Skip Navigation

Peter Sicinski, MD, PhD


Researcher


Researcher

  • Professor of Genetics, Harvard Medical School

Contact Information

  • Office Phone Number617-632-5005
  • Fax617-632-5006

Bio

Dr. Sicinski received his MD and PhD from the Warsaw Medical School in Poland. He spent two years as a visiting scientist at the Medical Research Council in Cambridge, England, before becoming a postdoctoral fellow with Dr. Robert A. Weinberg at Massachusetts Institute of Technology.

In 1997, Dr. Sicinski joined the faculty of Harvard and Dana-Farber Cancer Institute, where his research focuses on genes in the cell cycle machinery involved in normal cell development and cancer.

Recent Awards:

  • AACR-Gertrude B. Elion Cancer Research Award 2002
  • Abbott Bioresearch Center Award 2002
  • Scholar Leukemia & Lymphoma Society Award, 2003
  • Scholar of the Leukemia & Lymphoma Society 2005
  • Foreign Member, Polish Academy of Sciences 2005

Research

Cell Cycle Machinery in Development and Cancer

The cell cycle machinery is the ultimate recipient of oncogenic and mitogenic signals.Our laboratory studies the function of the cell cycle machinery at a molecular, cellular and organismal levels. We generated several knock-out and knock-in mouse strains which allow us to dissect the function of cell cycle proteins in normal development and in cancer formation or progression. We are also developing novel strains of mice that allow proteomic approaches to study the functions of cell cycle proteins (including cell cycle-independent functions) in various tissues of the living animal. The broad goal of these new directions is to combine the techniques of mouse germline manipulation with the new methods of proteome- and genome-wide analyses. We are also focusing on the functioning of the cell cycle machinery in various stem cell compartments.An important direction of our studies is to analyze the molecular functions of cell cycle proteins in human cancers.

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 03 28; 18(13):3167-3177.
View in: PubMed

Martinerie L, Manterola M, Chung SS, Panigrahi SK, Weisbach M, Vasileva A, Geng Y, Sicinski P, Wolgemuth DJ. Mammalian E-type cyclins control chromosome pairing, telomere stability and CDK2 localization in male meiosis. PLoS Genet. 2014 Feb; 10(2):e1004165.
View in: PubMed

Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR, Muncan V, Clevers H, Clarke AR, Sicinski P, Sansom OJ. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res. 2010 Oct 15; 70(20):8149-58.
View in: PubMed

Zeng L, Geng Y, Tretiakova M, Yu X, Sicinski P, Kroll TG. Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res. 2008 Aug 15; 68(16):6578-86.
View in: PubMed

Hanashiro K, Kanai M, Geng Y, Sicinski P, Fukasawa K. Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene. 2008 Sep 11; 27(40):5288-302.
View in: PubMed

Sicinski P, Zacharek S, Kim C. Duality of p27Kip1 function in tumorigenesis. Genes Dev. 2007 Jul 15; 21(14):1703-6.
View in: PubMed

Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005 Apr 18; 24(17):2909-15.
View in: PubMed

Ciemerych MA, Sicinski P. Cell cycle in mouse development. Oncogene. 2005 Apr 18; 24(17):2877-98.
View in: PubMed

Carthon BC, Neumann CA, Das M, Pawlyk B, Li T, Geng Y, Sicinski P. Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol. 2005 Feb; 25(3):1081-8.
View in: PubMed

Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13138-43.
View in: PubMed

Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001 Jun 28; 411(6841):1017-21.
View in: PubMed

Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci U S A. 2001 Jan 02; 98(1):194-9.
View in: PubMed

Solvason N, Wu WW, Parry D, Mahony D, Lam EW, Glassford J, Klaus GG, Sicinski P, Weinberg R, Liu YJ, Howard M, Lees E. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 2000 May; 12(5):631-8.
View in: PubMed

Kim HA, Pomeroy SL, Whoriskey W, Pawlitzky I, Benowitz LI, Sicinski P, Stiles CD, Roberts TM. A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron. 2000 May; 26(2):405-16.
View in: PubMed

Lam EW, Glassford J, Banerji L, Thomas NS, Sicinski P, Klaus GG. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem. 2000 Feb 04; 275(5):3479-84.
View in: PubMed

Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999 Oct 01; 18(19):5321-33.
View in: PubMed

Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell. 1999 Jun 11; 97(6):767-77.
View in: PubMed

Huard JM, Forster CC, Carter ML, Sicinski P, Ross ME. Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development. 1999 May; 126(9):1927-35.
View in: PubMed

Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P, Tennant RW, Weinberg RA, Yuspa SH, Conti CJ. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998 Aug 15; 12(16):2469-74.
View in: PubMed

Sicinski P, Weinberg RA. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia. 1997 Oct; 2(4):335-42.
View in: PubMed

Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 1996 Dec 05; 384(6608):470-4.
View in: PubMed

Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995 Aug 25; 82(4):621-30.
View in: PubMed

Geng Y, Sicinski P, Gorecki D, Barnard PJ. Developmental and tissue-specific regulation of mouse dystrophin: the embryonic isoform in muscular dystrophy. Neuromuscul Disord. 1991; 1(2):125-33.
View in: PubMed

Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989 Jun 30; 244(4912):1578-80.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Smith 922A
Boston MA, 02215
Get Directions

Top